Home » Stocks » MEIP

MEI Pharma, Inc. (MEIP)

Stock Price: $3.51 USD -0.16 (-4.23%)
Updated Mar 4, 2021 10:07 AM EST - Market open
Market Cap 411.85M
Revenue (ttm) 39.75M
Net Income (ttm) -36.35M
Shares Out 112.52M
EPS (ttm) -0.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 4
Last Price $3.51
Previous Close $3.66
Change ($) -0.16
Change (%) -4.23%
Day's Open 3.65
Day's Range 3.51 - 3.68
Day's Volume 128,582
52-Week Range 0.72 - 4.58

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
24/7 Wall Street - 3 weeks ago

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: IMAC, SB, TTI, ZIXI
Zacks Investment Research - 3 weeks ago

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of -46.67% and 340.09%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the...

PRNewsWire - 3 weeks ago

SAN DIEGO, Feb. 4, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quart...

Zacks Investment Research - 1 month ago

MEI Pharma, Inc. (MEIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 2 months ago

SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Phase 1b tr...

Seeking Alpha - 2 months ago

MEIP's pracinostat is a disaster; but zandelisib has always been its core asset. If all goes well, zandelisib may be in the market for r/r FL by 2021.

Business Wire - 2 months ago

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an...

PRNewsWire - 3 months ago

SAN DIEGO, Nov. 10, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quar...

Business Wire - 4 months ago

SAN DIEGO--(BUSINESS WIRE)---- $MEIP #ClassAction--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of MEI Pharma, Inc. (NASDAQ: MEIP) filed a class action complaint ...

PRNewsWire - 4 months ago

NEW YORK, Oct. 9, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and Jul...

Business Wire - 4 months ago

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against MEI Pharma, Inc. ("MEI Pharma" or "the Company") (NASDAQ: ME...

Newsfile Corp - 4 months ago

Los Angeles, California--(Newsfile Corp. - October 9, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MEI Pha...

Newsfile Corp - 4 months ago

New York, New York--(Newsfile Corp. - October 8, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between Augu...

Newsfile Corp - 4 months ago

Los Angeles, California--(Newsfile Corp. - October 8, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MEI Pha...

Newsfile Corp - 4 months ago

Los Angeles, California--(Newsfile Corp. - October 7, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MEI Pha...

Newsfile Corp - 4 months ago

Los Angeles, California--(Newsfile Corp. - October 6, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MEI Pha...

Newsfile Corp - 4 months ago

Los Angeles, California--(Newsfile Corp. - October 5, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MEI Pha...

Newsfile Corp - 5 months ago

New York, New York--(Newsfile Corp. - October 2, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between Augu...

Newsfile Corp - 5 months ago

Los Angeles, California--(Newsfile Corp. - October 2, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MEI Pha...

PRNewsWire - 5 months ago

TOKYO and SAN DIEGO, Oct. 2, 2020 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the ...

PRNewsWire - 5 months ago

NEW YORK, Sept. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and J...

Newsfile Corp - 5 months ago

New York, New York--(Newsfile Corp. - September 25, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in MEI Pharma, Inc. ("MEI Pharma" or the "Company")...

Newsfile Corp - 5 months ago

New York, New York--(Newsfile Corp. - September 23, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between A...

Newsfile Corp - 5 months ago

New York, New York--(Newsfile Corp. - September 18, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc.

PRNewsWire - 5 months ago

SAN DIEGO, Sept. 15, 2020 /PRNewswire/ -- MEI Pharma, Inc.

PRNewsWire - 5 months ago

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against MEI Pharma, Inc.

PRNewsWire - 5 months ago

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc.

Newsfile Corp - 5 months ago

New York, New York--(Newsfile Corp. - September 12, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc.

Business Wire - 5 months ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 2020, i...

Seeking Alpha - 5 months ago

MEI Pharma, Inc. (MEIP) CEO Dan Gold on Q4 2020 Results - Earnings Call Transcript

Other stocks mentioned: AAAU, BAR, DBP, DGL, GLD, GLDM, IAU, OUNZ, SGOL, UGL
PRNewsWire - 5 months ago

SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- MEI Pharma, Inc.

Newsfile Corp - 5 months ago

New York, New York--(Newsfile Corp. - September 4, 2020) -  Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the sec...

PRNewsWire - 6 months ago

SAN DIEGO, Sept. 4, 2020 /PRNewswire/ -- MEI Pharma, Inc.

PRNewsWire - 6 months ago

NEW YORK, Aug. 27, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against MEI Pharma, Inc.

Business Wire - 6 months ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 2020, i...

PRNewsWire - 6 months ago

NEW YORK, Aug. 21, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc.

Newsfile Corp - 6 months ago

New York, New York--(Newsfile Corp. - August 19, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against MEI Pharma, Inc.

PRNewsWire - 6 months ago

NEW YORK, Aug. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of MEI Pharm...

Business Wire - 6 months ago

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against MEI Pharma, Inc. ("MEI Pharma" or "the Company") (NASDAQ: ME...

Business Wire - 6 months ago

SAN DIEGO--(BUSINESS WIRE)---- $MEIP #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of MEI Pharma, Inc. (NASDAQ: MEIP) filed a class action complaint against ...

Business Wire - 6 months ago

LOS ANGELES--(BUSINESS WIRE)---- $MEIP #MEIP--SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MEI Pharma, Inc.

Newsfile Corp - 6 months ago

Los Angeles, California--(Newsfile Corp. - August 11, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MEI Ph...

Business Wire - 6 months ago

NEW YORK--(BUSINESS WIRE)-- #MEIP--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States D...

Business Wire - 6 months ago

LOS ANGELES--(BUSINESS WIRE)---- $MEIP #MEIP--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MEI Pharma, Inc.

Business Wire - 6 months ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of MEI Pharma, Inc. (NASD...

PRNewsWire - 6 months ago

NEW YORK, Aug. 10, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against MEI Pharma, Inc.

Zacks Investment Research - 6 months ago

MEI Pharma (MEIP) will provide financial updates when it reports fourth-quarter fiscal 2020 results.

PRNewsWire - 7 months ago

SAN DIEGO, Aug. 4, 2020 /PRNewswire/ -- MEI Pharma, Inc.

Seeking Alpha - 7 months ago

MEIP just disclosed its licensee will discontinue Pracinostat development sending shares down below $3. With ~$200MM cash and $0 debt, MEIP's fully diluted enterprise valuation totals ~$130MM ...

PRNewsWire - 7 months ago

NEW YORK, July 6, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of MEI Pharma, Inc. ("MEI Pharma" or...

About MEIP

MEI Pharma, a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also de... [Read more...]

Industry
Biotechnology
IPO Date
Dec 19, 2003
CEO
Daniel Gold
Employees
51
Stock Exchange
NASDAQ
Ticker Symbol
MEIP
Full Company Profile

Financial Performance

In 2020, MEI Pharma's revenue was $28.91 million, an increase of 488.26% compared to the previous year's $4.92 million. Losses were -$46.02 million, 173.6% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for MEI Pharma stock is "Strong Buy." The 12-month stock price forecast is 9.60, which is an increase of 173.89% from the latest price.

Price Target
$9.60
(173.89% upside)
Analyst Consensus: Strong Buy